Details

Autor(en) / Beteiligte

• Chung, J.H.
• Sanford, E.
• Johnson, A.
• Klempner, S.J.
• Schrock, A.B.
• Palma, N.A.
• Erlich, R.L.
• Frampton, G.M.
• Chalmers, Z.R.
• Vergilio, J.
• Rubinson, D.A.
• Sun, J.X.
• Chmielecki, J.
• Yelensky, R.
• Suh, J.H.
• Lipson, D.
• George, T.J.
• Elvin, J.A.
• Stephens, P.J.
• Miller, V.A.
• Ross, J.S.
• Ali, S.M.

Titel

Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes

Ist Teil von

• Annals of oncology, 2016-07, Vol.27 (7), p.1336-1341

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Squamous cell cancers of the anal canal (ASCC) are increasing in frequency and lack effective therapies for advanced disease. Although an association with human papillomavirus (HPV) has been established, little is known about the molecular characterization of ASCC. A comprehensive genomic analysis of ASCC was undertaken to identify novel genomic alterations (GAs) that will inform therapeutic choices for patients with advanced disease. Hybrid-capture-based next-generation sequencing of exons from 236 cancer-related genes and intronic regions from 19 genes commonly rearranged in cancer was performed on 70 patients with ASCC. HPV status was assessed by aligning tumor sequencing reads to HPV viral genomes. GAs were identified using an established algorithm and correlated with HPV status. Sixty-one samples (87%) were HPV-positive. A mean of 3.5 GAs per sample was identified. Recurrent alterations in phosphoinositol-3-kinase pathway (PI3K/AKT/mTOR) genes including amplifications and homozygous deletions were present in 63% of cases. Clinically relevant GAs in genes involved in DNA repair, chromatin remodeling, or receptor tyrosine kinase signaling were observed in 30% of cases. Loss-of-function mutations in TP53 and CDKN2A were significantly enhanced in HPV-negative cases (P < 0.0001). This is the first comprehensive genomic analysis of ASCC, and the results suggest new therapeutic approaches. Differing genomic profiles between HPV-associated and HPV-negative ASCC warrants further investigation and may require novel therapeutic and preventive strategies.